Arena Pharmaceuticals' CEO Jack Lief talks to The Wall Street Transcript
NEW YORK--(BUSINESS WIRE)--May 8, 2001--The Wall Street Transcript
has published an in-depth interview with Jack Lief, CEO of Arena
Pharmaceuticals (Nasdaq:ARNA), in which he talks at length about the
Click here to listen to a live webcast for the RBC Dain Rauscher
Wessels Biotechnology "Gene To Drugs" Genomics & Life Sciences
Conference Issue http://www.twst.com/dr3conference.html
The entire 2,300-word interview is available online at
Lief gives an overview of the company. "We're a three-year old
company that focuses on a technology that significantly reduces the
gene discovery to drug discovery process. We look at a particular type
of drugable target of cell surface receptors, G protein-coupled
receptors (GPCRs). Our technology allows us to reduce the time from
the receptor gene discovery to the setup of an assay from perhaps a
decade to a period of only a few months. And that, as you can imagine,
allows us a large number of targets that we can address."
Lief explains, "With the Human Genome Project coming to
completion, we see that there will be a huge number of new drugable
target opportunities that are going to be becoming available. For
diseases that have only been addressed via symptomatic relief, now
there is an opportunity to actually cure those types of diseases
because receptors are such an important part of how normal cells and
normal physiology work in the body."
Looking forward, Lief states, "We have strong revenue growth,
which will drive our income statement, both near-term and long-term.
We have a huge new drug discovery pipeline, which will discover lead
compounds at perhaps 800 different, highly drugable receptor targets.
There has never been a company, to my knowledge, that has gone after
an entire large class of genomic targets in this fashion to
essentially finish the drug discovery process in a relatively short
period of time. So I think the short-term prospects are very good for
Arena. The medium and long-term prospects are even better."
This interview is part of a 159-page RBC Dain Rauscher Wessels
Biotechnology "Gene To Drugs" Genomics & Life Sciences Conference
Issue available at http://www.twst.com/info/info341.htm or by calling
The Wall Street Transcript does not endorse the views of any
interviewees nor does it make stock recommendations. For subscription
information call 800/246-7673.